Literature DB >> 36133435

Comprehensive Analysis of Novel Genes and Pathways Associated with Osteogenic Differentiation of Adipose Stem Cells.

Qiuni Gao1, Xiaorong Ma2, Zuoliang Qi3.   

Abstract

Background: Adipose-derived stem cells (ADSCs) are an important alternative source of mesenchymal stem cells (MSCs) and show great promise in tissue engineering and regenerative medicine applications. However, identifying the novel genes and pathways and finding the underlying mechanisms regulating ADSCs osteogenic differentiation remain urgent.
Methods: We downloaded the gene expression profiles of GSE63754 and GSE37329 from the Gene Expression Omnibus (GEO) Database. We derived differentially expressed genes (DEGs) before and after ADSC osteogenic differentiation, followed by Gene Ontology (GO) functional and KEGG pathway analysis and protein-protein interaction (PPI) network analysis. 211 differentially expressed genes (142 upregulated genes and 69 downregulated genes) were aberrantly expressed. GO analysis revealed that these DEGs were associated with extracellular matrix organization, protein extracellular matrix, and semaphorin receptor binding. Conclusions: Our study provides novel genes and pathways that play important roles in regulating ADSC osteogenic differentiation, which may have potential therapeutic targets for clinic.
Copyright © 2022 Qiuni Gao et al.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36133435      PMCID: PMC9484926          DOI: 10.1155/2022/4870981

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.464


1. Introduction

Millions of patients around the world suffer from bone defects caused by tumors, infections, and trauma, and their repair and treatment are a major problem [1]. Over 10 million bone transplants are performed worldwide each year, and the number is still growing at a rate of 10% annually [2]. Presently, autologous bone transplantation and allogeneic bone transplantation are the two main surgical options for treating bone defects and nonunion [3, 4]. Autologous bone transplants are a common treatment for bone defects, but their use is limited due to their limited source, poor plasticity, and damaging to the donor site [5]. Allogeneic bone transplantation results in a significantly higher rate of postoperative complications, which has exceeded 30%, and includes fractures, insufficiency, and infections [6, 7]. By creating replacements for natural bone grafts, bone tissue engineering aims to address the shortcomings [8]. As well as having the ability to form on demand, it should also easy to be prepared. Several advances have been made recently, including the development of human ADSCs that can perform paracrine functions as well as multilineage differentiation [9-11]. As a result of their properties, ADSCSs are especially useful in bone tissue engineering. Transplanting human ADSCs as a prospective treatment has recently received some attention [12, 13]. The treatment of bone trauma with autologous cells is therefore relatively promising. Transcriptional, posttranscriptional, and epigenetic factors regulate osteogenic differentiation of ADSCs [14]. A high-efficiency osteoinductive factor is also required as part of repairing bone tissue [15]. Wnt, PI3K/Akt, and MAPK signaling pathways were associated with osteogenic differentiation of ADSCs [16]. So, we have focused on developing osteoinductive factors that are effective. To uncover the molecular mechanisms of osteogenesis, further research is required. ADSCs have become a hot spot in bone tissue engineering research because of their abundant sources and easy access to materials. However, the molecular biological mechanism of osteogenic differentiation of ADSCs has not been fully elucidated [17]. With the rapid development of big data and bioinformatics, as well as the application of ADSCs in the field of clinical medicine, some scholars have carried out RNA microarray and sequencing studies on the osteogenic differentiation of ADSCs to further explore the role of these RNAs in the osteogenesis of ADSCs [18, 19]. Molecular biological mechanisms during differentiation remains elusive. Molecular biology and functional genomics utilize microarray profiling to discover genes that are upregulated or downregulated, respectively [20, 21]. Therefore, in this study, bioinformatics methods were used to screen the differentially expressed genes and their involved signaling pathways during the osteogenic differentiation of ADSCs, in order to explore the molecular biological mechanism of potential key genes during the osteogenic differentiation of ADSCs. We first identified the differentially expressed genes (DEGs) from two microarray datasets selected from Gene Expression Omnibus (GEO) database. A bioinformatics approach was used to analyze the signaling pathway involving novel genes and to construct a protein–protein interaction (PPI) network. To sum up, this study found the potential key genes and the pathways involved in the osteogenic differentiation of ADSCs by mining the data related to the osteogenic differentiation of ADSCs in GEO database. These results may provide new ideas and a basis for further experimental studies to explore the genesis, development, and molecular biological mechanism of osteogenic differentiation of ADSCs in the future.

2. Methods

2.1. Data Collection

Transcript profile data on osteogenic differentiation between ADSCSs and noninduced ADSCs were derived from NCBI GEO databases (http://www.ncbi.nlm.nih.gov/geo/). GSE63754 (3 undifferentiated ADSCs and 3 osteogenic differentiated ADSCs) and GSE37329 (3 ADSCs and 2 ADSC-derived osteocytes) are the accession numbers for the collections. All of these ADSCSDs were collected from human tissues and underwent osteogenic induction.

2.2. Identification of Differentially Expressed Gene

R software and Bioconductor packages were applied to data mining and statistical analyses. The Limma package was subsequently used for identifying DEGs. P < 0.05 and log2 fold change (log2FC) > 1 or < −1 were considered as the cutoff values for DEGs to be considered statistically significant. R software was used to produce heat maps of common significant differentially expressed genes between GSE63754 and GSE37329.

2.3. GO and KEGG Enrichment Analysis

GSEA was performed using GSEA 3.0 (http://www.broadinstitute.org/gsea/). Geneset with a P value less than 0.05 was considered to be significantly enriched. GO enrichment analysis was performed using the Gene Ontology Consortium Enrichment analysis tool (http://www.geneontology.org). To analyze the enriched biological processes (BPs), cellular components (CCs), molecular functions (MFs), and pathways of DEGs, GO analysis and KEGG pathway enrichment analysis were performed with the online tools DAVID (https://david.ncifcrf.gov/) and MetADSCsape (http://metADSCsape.org).

2.4. PPI Network Construction

STRING database (http://string-db.org) and Cytoscape software (Version 3.4.0) were used to identify 142 upregulated DEGs and 69 downregulated DEGs. The network was visualized using Cytoscape, a widely-used tool for exploring interactions among biomolecules, including proteins and genes.

2.5. Statistical Methods

These statistics were generated using the R software and were two-sided. P values less than 0.05 were considered statistically significant.

3. Results

3.1. DEGs of GSE63754 and GSE37329

Differential gene expression analyses were visualized by volcano plots. To explore the biological classification of the DEGs overlapping in the dataset, all genes were identified in the two datasets using DAVID and MetADSCsape software. The genes are commonly regulated (P < 0.05 and log2 fold change (log2FC) > 1 or < −1) in GSE63754. Then, we compared the gene expression profiles between ADSCSs before and after osteogenic induction by using GSEA. Figures 1(a)–1(c) show DEGs in GSE63754. Figures 1(d)–1(f) show DEGs in GSE37329.
Figure 1

DEGs of GSE63754 and GSE37329. (a–d) Volcano plot: the volcano plot was constructed using the fold change values and P-adjust. Red dots indicate upregulated genes; blue dots indicate downregulated genes. (c–f) Gene set enrichment analysis (GSEA) of two significantly enriched classes of genes: ADSCs and noninduced ADSC datasets.

3.2. GO and KEGG Pathway Enrichment Analysis

Through GO and KEGG analysis, we found that DEGs of GSE63754, extracellular matrix organization, ossification, bone mineralization, regulation of inflammatory response, and bone remodeling were mainly showed enrichment in the biological process (BP) categories. As for cellular component (CC) categories, collagen-containing extracellular matrix, high-density lipoprotein particle, plasma lipoprotein particle, plasma lipoprotein particle, and protein-lipid complex were detected; and in molecular function (MF), receptor ligand activity, extracellular matrix structural constituent, growth factor activity, Wnt-protein binding, and cytokine receptor binding. With regard to KEGG pathway, cytokine-cytokine receptor interaction, ECM-receptor interaction, PI3K-Akt signaling pathway, PPAR signaling pathway, and cholesterol metabolism were the top pathways involved in the osteogenic differentiation of ADSCs (Figures 2(a)–2(d)). Gene Ontology analyses of upregulated and downregulated DEGs are listed in Tables 1 and 2.
Figure 2

GO and KEGG pathway enrichment analysis. (a–h) Gene Ontology (GO) analysis and enriched KEGG signaling pathways were selected to demonstrate the primary biological actions of major potential genes. Colors represent the significance of differential enrichment, the size of the circles represents the number of genes, the larger the circle, the greater the number of genes. In the enrichment result, P < 0.05 or FDR < 0.05 is considered to be a meaningful pathway (enrichment score with −log10 (P) of more than 1.3). BP: biological process; CC: cellular component; MF: molecular function.

Table 1

Gene Ontology analyses of upregulated DEGs.

OntologyIDDescriptionGeneRatioBgRatio P value P.adjust Q value
BPGO: 1903532Positive regulation of secretion by cell13/130399/186704.36e-060.0090.008
BPGO: 0051047Positive regulation of secretion13/130428/186709.27e-060.0090.008
BPGO: 0002532Production of molecular mediator involved in inflammatory response6/13072/186701.09e-050.0090.008
BPGO: 0070542Response to fatty acid6/13086/186703.03e-050.0140.012
BPGO: 0050727Regulation of inflammatory response13/130485/186703.44e-050.0140.012
CCGO: 0034358Plasma lipoprotein particle4/13437/197171.13e-040.0120.011
CCGO: 1990777Lipoprotein particle4/13437/197171.13e-040.0120.011
CCGO: 0032994Protein-lipid complex4/13439/197171.39e-040.0120.011
CCGO: 0099061Integral component of postsynaptic density membrane4/13450/197173.69e-040.0170.015
CCGO: 0099146Intrinsic component of postsynaptic density membrane4/13453/197174.61e-040.0170.015
MFGO: 0016709Oxidoreductase activity4/13039/176971.87e-040.0650.058
MFGO: 0004745Retinol dehydrogenase activity3/13020/176974.03e-040.0700.063
MFGO: 0004497Monooxygenase activity5/13099/176978.16e-040.0940.084
KEGGhsa00982Drug metabolism-cytochrome P4508/6671/80769.12e-081.48e-051.40e-05
KEGGhsa00350Tyrosine metabolism5/6636/80769.69e-067.85e-047.45e-04
KEGGhsa00071Fatty acid degradation4/6644/80764.32e-040.0230.022
KEGGhsa04979Cholesterol metabolism4/6650/80767.07e-040.0290.027
KEGGhsa00830Retinol metabolism4/6668/80760.0020.0730.069
Table 2

Gene Ontology analyses of downregulated DEGs.

OntologyIDDescriptionGeneRatioBgRatio P value P.adjust Q value
BPGO: 0010721Negative regulation of cell development12/66344/186702.55e-095.10e-063.85e-06
BPGO: 0060537Muscle tissue development12/66408/186701.71e-081.71e-051.29e-05
BPGO: 0014706Striated muscle tissue development11/66390/186701.10e-077.34e-055.54e-05
BPGO: 0050768Negative regulation of neurogenesis9/66295/186709.14e-074.57e-043.45e-04
BPGO: 0051961Negative regulation of nervous system development9/66315/186701.57e-066.29e-044.75e-04
CCGO: 0005913Cell-cell adherens junction4/66117/197176.39e-040.0260.024
CCGO: 0045121Membrane raft6/66315/197176.44e-040.0260.024
CCGO: 0098857Membrane microdomain6/66316/197176.55e-040.0260.024
CCGO: 0098589Membrane region6/66328/197177.95e-040.0260.024
CCGO: 0016342Catenin complex2/6629/197170.0040.0920.084
MFGO: 0045499Chemorepellent activity4/6327/176972.41e-065.22e-044.61e-04
MFGO: 0001158Enhancer sequence-specific DNA binding5/63119/176976.50e-050.0050.005
MFGO: 0030215Semaphorin receptor binding3/6323/176977.24e-050.0050.005
MFGO: 0035326Enhancer binding5/63133/176971.10e-040.0060.005
MFGO: 0005539Glycosaminoglycan binding6/63229/176971.61e-040.0070.006
KEGGhsa04550Signaling pathways regulating pluripotency of stem cells5/40143/80766.48e-040.0640.061
KEGGhsa04350TGF-beta signaling pathway4/4094/80760.0010.0640.061
In GSE37329 dataset, regulation of blood pressure, chemokine production, regulation of inflammatory response, regulation of chemokine production, and regulation of fat cell differentiation were detected in BP. In CC categories, we found collagen-containing extracellular matrix, synaptic membrane, presynapse, exocytic vesicle, and transport vesicle were mainly shown. As for MF, glycosaminoglycan binding, G protein-coupled peptide receptor activity, peptide receptor activity, Wnt-protein binding, and extracellular matrix structural constituent were figured out. The results of KEGG pathway demonstrated that drug metabolism-cytochrome P450, tyrosine metabolism, neuroactive ligand-receptor interaction, and vascular smooth muscle contraction were important in the osteogenic differentiation of ADSCs (Figures 2(e)–2(h)).

3.3. Overlapping DEGs of Datasets

The commonly and differentially expressed genes in GSE63754 and GSE37329 during osteogenic differentiation of ADSCs were identified (P < 0.05 and log2 fold change (log2FC) > 1 or < −1). To investigate the biological classification of the 142-overlapping upregulated DEGs and 69-overlapping downregulated DEGs, DAVID and MetADSCsape software packages were used to identify genes in the two datasets. In 142 upregulated overlapping DEGs, we found that positive regulation of secretion and positive regulation and fatty acid degradation were in the center of GO network. In 69-overlapping downregulated DEGs, striated muscle tissue development and muscle tissue development were significantly different (Figures 3(a)–3(d)).
Figure 3

Overlapping DEGs of datasets. (a–d) Gene Ontology (GO) analysis and enriched KEGG signaling pathways were selected to demonstrate the primary biological actions of major potential genes. Colors represent the significance of differential enrichment, the size of the circles represents the number of genes, the larger the circle, the greater the number of genes. In the enrichment result, P < 0.05 or FDR < 0.05 is considered to be a meaningful pathway (enrichment score with −log10 (P) of more than 1.3). BP: biological process; CC: cellular component; MF: molecular function.

3.4. Key Candidate Gene Identification with DEG PPI Network

Based on the STRING online database and Cytoscape software, DEG protein–protein interaction (PPI) network complex was constructed. We collected 142-overlapping upregulated DEGs and 69-overlapping downregulated DEGs to create the PPI network. The central node genes might potentially play an important role in regulating ADSC osteogenic differentiation (Figure 4).
Figure 4

Key candidate gene identification with DEG PPI network. PPI network of the common significant differentially expressed genes was constructed. A total of 142-overlapping upregulated DEGs and 69-overlapping downregulated DEGs were identified by Cytoscape. PPI: protein–protein interaction.

4. Discussion

In the field of tissue engineering, the use of biocompatible scaffolds has increased in recent years [22]. The ability to self-renew, the proliferation potential, and the multipotency of ADSCs make them attractive for regenerative medicine applications [23, 24]. Since ADSCs are readily available and easy to obtain in large quantities, they have become promising seed cells for bone tissue engineering [25]. In order for ADSC-based therapies to be successful in vivo, they must be paired with a substance that facilitates their osteogenic differentiation in vivo [26]. Thus, it is critical that we understand the molecular mechanisms that underlie osteogenic differentiation in ADSCSs. We firstly analyses GSE63754 (3 undifferentiated ADSCs and 3 osteogenic differentiated ADSCs) and GSE37329 (3 ADSCs and 2 ADSC-derived osteocytes). Because of this study, we found 211 significant DEGs common to both microarrays (142 upregulated and 69 downregulated). The most enrichment is extracellular matrix organization in the BP category. The extracellular matrix is an active factor in cellular differentiation, and modifying its composition can greatly influence osteogenic differentiation of mesenchymal stem cells (Hwang et al., 2015). Other BP, such as ossification, bone mineralization, regulation of inflammatory response, and bone remodeling, were also showed enrichment. ADSCSs undergo osteogenic differentiation, thus, a regulation of genes negatively related to cell proliferation is observed. In CC categories, collagen-containing extracellular matrix, high-density lipoprotein particle, plasma lipoprotein particle, plasma lipoprotein particle, and protein-lipid complex showed the highest enrichment score. It is interesting to note that two of the top eight CCs that are highly associated with ADSCS osteogenic differentiation are either located in the extracellular space or are located in the cell membrane, indicating that cell-to-cell signaling plays a crucial role in osteogenic differentiation. In MF categories, except chemorepellent activity, enhancer sequence-specific DNA binding, and semaphorin receptor binding, Wnt-protein binding and Wnt-activated receptor activity are most important factors. ADSCs differentiate into osteoblasts through Wnt proteins, and bone formation occurs via these proteins. It is possible that disrupting Wnt signaling pathway might significantly affect bone regeneration and remodeling [27-29]. ADSCs differ in their osteogenic differentiation in response to a variety of signaling pathways, including ERK1/2, Wnt, PI3K/Akt, and BMP-Smad. These proteins enable ADSCs to differentiate into osteoblasts and lead to bone formation. In KEGG pathway, the top significantly changed pathways of upregulated genes are related to drug metabolism-cytochrome P450, tyrosine metabolism, fatty acid degradation, cholesterol metabolism, retinol metabolism, and PPAR signaling pathway. ADSCSs that differentiate into osteoblasts have downregulated genes influenced by the adipogenesis pathway. ADSCs were targeted by several pathways which affected osteogenic differentiation and, as a result, affected bone formation. In our study, we constructed a PPI network which is composed of the associated genes. PODXL is a negatively charged sialic acid glycoprotein, belonging to the type I transmembrane glycoprotein, which has been reported to be associated with poor prognosis in oral squamous cell carcinoma, colon cancer, glioblastoma, and breast cancer and has an impact on cell adhesion and migration. It has a promoting effect, and PODXL is an important condition for maintaining the stability of the pod cytoskeleton [30]. SEMA3D is a member of the class III semaphorin family and is a marker of osteoarthritis. Class III semaphorins are involved in normal bone homeostasis and bone pathology and have a complex relationship between osteoblasts and osteoclasts which has the potential to treat bone disease [31]. The ADGRG6 single nucleotide polymorphism is associated with human height, and its deletion in osteoblasts may delay osteoblast differentiation and bone formation, resulting in shortened body length and reduced bone mass in mice [32-34]. CADM3 is an immunoglobulin adhesion molecule belonging to the Nectin molecule-like family of proteins [35]. The constitutive expression level of RERG in calvaria was 1000-fold higher than in femoral osteoblasts; during osteogenic induction, RERG expression was downregulated in calvarial osteoblasts and upregulated in femoral osteoblasts [20]. The osteocytes of the skull are fundamentally different from those of the femur and respond differently to a range of stimuli. These site-specific differences may have important implications in developing strategies to address metabolic bone disease [36]. APCDD1 is an inhibitor of Wnt signaling pathway, which can promote the adipogenic differentiation and lipid anabolism of bone marrow stromal cells [37]. NRCAM may modulate geometric parameters of the femoral neck and contribute to an improved understanding of osteoporosis and pathophysiological mechanisms [38, 39]. The target genes supported by these literatures are related to bone homeostasis, osteogenic differentiation, bone diseases, and metabolism, which supports the feasibility of this study to explore the underlying molecular mechanisms during the osteogenic differentiation of adipose-derived stem cells [40]. The drawback of our study is the lack of functional cellular and animal experiments for validation to explore the occurrence, development, and molecular biology of osteogenic differentiation of ADSCs. In conclusion, based on two transcript profile data on osteogenic differentiation between ADSCs and noninduced ADSC datasets and comprehensive analysis, we have identified several genes and pathways that could be crucial to osteogenic differentiation of ADSCs. Understanding of how ADSCs differentiate into osteoblasts could be improved significantly by our new findings. Moreover, manipulation of these genes and pathways may lead to bone regeneration and tissue engineering.
  40 in total

Review 1.  Lifestyle effects on hematopoiesis and atherosclerosis.

Authors:  Matthias Nahrendorf; Filip K Swirski
Journal:  Circ Res       Date:  2015-02-27       Impact factor: 17.367

2.  Differences in the Osteogenic Differentiation Capacity of Omental Adipose-Derived Stem Cells in Obese Patients With and Without Metabolic Syndrome.

Authors:  Wilfredo Oliva-Olivera; Antonio Leiva Gea; Said Lhamyani; Leticia Coín-Aragüez; Juan Alcaide Torres; Maria Rosa Bernal-López; Pedro Pablo García-Luna; Salvador Morales Conde; Sonia Fernández-Veledo; Rajaa El Bekay; Francisco José Tinahones
Journal:  Endocrinology       Date:  2015-09-15       Impact factor: 4.736

3.  Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.

Authors:  Xiaoqing Hu; Xin Zhang; Linghui Dai; Jingxian Zhu; Zhuqing Jia; Weiping Wang; Chunyan Zhou; Yingfang Ao
Journal:  Stem Cells Dev       Date:  2012-11-02       Impact factor: 3.272

4.  Surface modification by allylamine plasma polymerization promotes osteogenic differentiation of human adipose-derived stem cells.

Authors:  Xujie Liu; Qingling Feng; Akash Bachhuka; Krasimir Vasilev
Journal:  ACS Appl Mater Interfaces       Date:  2014-06-11       Impact factor: 9.229

5.  Genome-wide screening of functional long noncoding RNAs in the epicardial adipose tissues of atrial fibrillation.

Authors:  Xin Shi; Xuelian Shao; Ban Liu; Mengwei Lv; Pratik Pandey; Changfa Guo; Ruilin Zhang; Yangyang Zhang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-03-05       Impact factor: 5.187

6.  Promoting Osteogenic Differentiation of Human Adipose-Derived Stem Cells by Altering the Expression of Exosomal miRNA.

Authors:  Shude Yang; Shu Guo; Shuang Tong; Xu Sun
Journal:  Stem Cells Int       Date:  2019-07-01       Impact factor: 5.443

7.  Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial.

Authors:  Ridhima Vij; Kevin A Stebbings; Hosu Kim; Hyeonggeun Park; Donna Chang
Journal:  Stem Cell Res Ther       Date:  2022-03-03       Impact factor: 6.832

8.  The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process.

Authors:  Katarzyna Kornicka; Krzysztof Marycz; Krzysztof Andrzej Tomaszewski; Monika Marędziak; Agnieszka Śmieszek
Journal:  Oxid Med Cell Longev       Date:  2015-07-12       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.